Life Sciences

Lilly to pay $1.4B for alleged off-label promotion

Pharma Compliance Alert, January 21, 2009

Eli Lilly’s tab for allegedly promoting its antipsychotic Zyprexa for off-label uses topped $2.6 billion after it agreed to pay $1.42 billion to resolve civil and criminal allegations with the federal government.

Post a Comment





Please enter your comment below:


Please enter the text below:


Most Popular